Literature DB >> 2106769

The design of future cost-benefit studies.

A Maynard1.   

Abstract

An economic evaluation is designed to prioritize expenditure, aid decision making, and inform medical audit. A good economic evaluation is explicit and clearly describes the alternative therapies to be evaluated. The evaluation takes into consideration the cost of each component and measures outcome in economic benefit and physical, social, and psychologic well-being. A variety of approaches can be used to assess quality of life, and a good economic evaluation will use a range of measures. Costs and outcomes of health care interventions typically accrue across time periods, and the analysis must allow for this. Similarly, data must answer the question; how much does it cost to identify one additional unit of benefit? Because all evaluations are imprecise both in cost and outcome, sensitivity analysis is needed to determine the effect that different assumptions have on the results.

Mesh:

Year:  1990        PMID: 2106769     DOI: 10.1016/s0002-8703(05)80058-4

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 2.  Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

Authors:  T van der Weijden; J A Knottnerus; A J Ament; H E Stoffers; R P Grol
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

Review 3.  Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.

Authors:  K S Woo; H D White
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

4.  Equivalence and noninferiority trials - are they viable alternatives for registration of new drugs? (III).

Authors:  Cornel Pater
Journal:  Curr Control Trials Cardiovasc Med       Date:  2004-08-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.